Ceribell, Inc. (CBLL) Stock Analysis and Metrics

Ceribell

NASDAQ: CBLL

$16.90 ▲ +0.62 (+3.81%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap613.16 Mn

P/E-10.16

P/S6.45

Div. Yield0.00

Total Debt (Qtr)19.92 Mn

Revenue Growth (1y) (Qtr)29.30

Add ratio to table…

About

Ceribell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a point of care EEG platform designed for the acute care setting. By combining proprietary highly portable hardware with AI powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients at risk of seizures. Ceribell, Inc. operates in the medical technology industry, specifically within neurological monitoring and EEG solutions.

We generate revenue primarily from two recurring sources. The first is the sale of single use disposable Wearables that are intended for one patient use. The second is a monthly subscription fee charged to hospital customers for access to Clarity, the recorder device and the cloud based portal. This subscription provides ongoing use of the seizure detection algorithm and related software updates. Revenue is derived from healthcare providers in the United States who adopt the Ceribell System in their acute care facilities.

Ceribell, Inc. holds a strong competitive position in the EEG market as a first mover with regulatory clearances that competitors lack. In May 2023 the company received FDA 510k clearance for Clarity, the first device cleared for diagnosing electrographic status epilepticus in adult patients. In December 2025 the FDA granted 510k clearance for the company's proprietary delirium monitoring solution, marking it as the first and only FDA cleared delirium detection and monitoring device. The company also secured a New Technology Add on Payment from CMS for its Clarity algorithm, providing additional reimbursement incentives for hospitals. Key competitors include conventional EEG providers such as Natus Medical Incorporated and Nihon Kohden Corporation, as well as emerging rapid EEG companies like Zeto. Ceribell differentiates itself through its AI powered algorithms, a robust intellectual property portfolio of 58 issued and pending patents, and a clinical evidence base of over 140 peer reviewed publications. These advantages support its goal of becoming the standard of care for seizure detection and management in the acute care setting.

The company serves hospitals and acute care facilities across the United States. As of December 31 2025 the Ceribell System had been adopted by more than 600 hospitals ranging from top academic medical centers to small community hospitals. The customer base includes intensive care units, emergency departments and other acute care settings where patients are at risk of seizures, delirium or stroke. Specific customer names are not disclosed in the filing, but the company indicates that its clients span a broad spectrum of healthcare providers seeking EEG monitoring solutions.

Investment Thesis

▲ Bull case

CeriBell, Inc. is positioned to capitalize on a structural shift in neurological care driven by the convergence of EEG technology with critical ICU conditions, particularly through its delirium monitoring solution which has received supportive CMS NTAP proposed rulemaking offering up to $2,171 in incremental reimbursement per patient—a potential catalyst that management did not heavily promote but could significantly accelerate adoption and monetization starting Q4 2026 or Q1 2027, directly expanding the addressable market beyond seizure management into the $1 billion delirium market where CeriBell holds the only FDA-cleared diagnostic tool, creating a defensible first-mover advantage with strong clinical validation from the ongoing Vanderbilt study highlighting the pathophysiological overlap between seizure and delirium in ICU patients.
The company’s commercial expansion strategy is demonstrating sustainable momentum beyond headline account growth, as evidenced by the maturation of its newly hired sales team where over 85% of reps with 12+ months tenure have contributed to the active account base and 100% have generated purchase orders—a leading indicator of future productivity that management acknowledged but did not emphasize as a multi-year growth engine, with expectations of further step-up in 2026 and acceleration in 2027 as more reps reach peak productivity, supported by the regional health systems initiative targeting top-down engagement with system-level executives that is unlocking larger, stickier deals and reducing sales cycle friction through centralized coordination across territories.
CeriBell’s gross margin resilience at 87% in Q1 despite elevated China-sourced inventory tariffs reveals underlying operational strength, with management confirming that cost mitigation initiatives from 2025 have nearly fully offset tariff impacts and that the shift to Vietnam-sourced inventory—though not yet reflected in COGS due to FIFO accounting—will deliver margin expansion in the back half of 2026, providing a hidden leverage point to profitability that is not fully priced into current guidance, especially as the company maintains confidence in sustaining high-80% gross margins throughout the year while scaling revenue toward its $112–116 million 2026 target.
The company’s total addressable market has nearly doubled to approximately $3.5 billion in the U.S. alone, driven by expanding indications beyond core seizure management into neonate, pediatric, delirium, and LVO stroke applications—a structural shift that management framed as evolutionary but which represents a fundamental de-risking of revenue concentration, with early traction in neonate (five pilot sites converted to full launch) and pediatric ER use cases demonstrating real-world clinical utility that avoids costly downstream procedures like lumbar punctures and ICU admissions, creating organic pull-through demand that is underappreciated in near-term models but poised to drive significant same-store growth and account expansion as utilization per account continues to rise, already showing top accounts monitoring three times as many patients as averages.

CeriBell, Inc. is positioned to capitalize on a structural shift in neurological care driven by the convergence of EEG technology with critical ICU conditions, particularly through its delirium monitoring solution which has received supportive CMS NTAP proposed rulemaking offering up to $2,171 in incremental reimbursement per patient—a potential catalyst that management did not heavily promote but could significantly accelerate adoption and monetization starting Q4 2026 or Q1 2027, directly expanding the addressable market beyond seizure management into the $1 billion delirium market where CeriBell holds the only FDA-cleared diagnostic tool, creating a defensible first-mover advantage with strong clinical validation from the ongoing Vanderbilt study highlighting the pathophysiological overlap between seizure and delirium in ICU patients.
The company’s commercial expansion strategy is demonstrating sustainable momentum beyond headline account growth, as evidenced by the maturation of its newly hired sales team where over 85% of reps with 12+ months tenure have contributed to the active account base and 100% have generated purchase orders—a leading indicator of future productivity that management acknowledged but did not emphasize as a multi-year growth engine, with expectations of further step-up in 2026 and acceleration in 2027 as more reps reach peak productivity, supported by the regional health systems initiative targeting top-down engagement with system-level executives that is unlocking larger, stickier deals and reducing sales cycle friction through centralized coordination across territories.
CeriBell’s gross margin resilience at 87% in Q1 despite elevated China-sourced inventory tariffs reveals underlying operational strength, with management confirming that cost mitigation initiatives from 2025 have nearly fully offset tariff impacts and that the shift to Vietnam-sourced inventory—though not yet reflected in COGS due to FIFO accounting—will deliver margin expansion in the back half of 2026, providing a hidden leverage point to profitability that is not fully priced into current guidance, especially as the company maintains confidence in sustaining high-80% gross margins throughout the year while scaling revenue toward its $112–116 million 2026 target.
The company’s total addressable market has nearly doubled to approximately $3.5 billion in the U.S. alone, driven by expanding indications beyond core seizure management into neonate, pediatric, delirium, and LVO stroke applications—a structural shift that management framed as evolutionary but which represents a fundamental de-risking of revenue concentration, with early traction in neonate (five pilot sites converted to full launch) and pediatric ER use cases demonstrating real-world clinical utility that avoids costly downstream procedures like lumbar punctures and ICU admissions, creating organic pull-through demand that is underappreciated in near-term models but poised to drive significant same-store growth and account expansion as utilization per account continues to rise, already showing top accounts monitoring three times as many patients as averages.

▼ Bear case

CeriBell, Inc. faces significant near-term profitability headwinds driven by escalating and nonlinear IP litigation expenses, which totaled $5.6 million in Q1 2026—considerably higher than the $1–2 million quarterly run-rate seen in prior periods—and are expected to remain elevated through Q2 as the company prepares for and undergoes trial, with management acknowledging this as peak spend that will only moderate later in the year, creating a drag on adjusted EBITDA that could persist despite revenue growth and potentially delay cash-flow breakeven expectations if litigation costs remain elevated or increase due to unfavorable rulings or extended discovery.
The company’s growth trajectory remains heavily dependent on seasonal ICU census fluctuations, with management explicitly acknowledging sequential moderation in headband utilization during Q2 and Q3 due to warmer months reducing ICU admissions—a predictable but material headwind that offsets same-store growth gains and creates volatility in quarterly performance that may lead to periodic misses against consensus estimates, particularly as the guidance raise of $1 million was based on Q1 strength without fully accounting for the typical seasonal decline in utilization that has historically affected Q2 and Q3 results, making full-year achievement of the $112–116 million revenue range contingent on stronger-than-expected new account additions to offset predictable seasonal softness in usage per account.
Despite record net new account additions of 33 in Q1, CeriBell’s penetration in its core seizure market remains below 4% of the 6,000 U.S. hospitals offering acute care services, indicating that the addressable market expansion into new indications like delirium and LVO stroke may be overstated in near-term impact, as management conceded that commercial launch of delirium solution is not expected until Q4 2026 or Q1 2027 and that pediatric and neonate adoption requires months-long sales cycles similar to core accounts, meaning these initiatives are unlikely to contribute meaningfully to 2026 revenue beyond incremental usage within existing accounts, creating a risk that market enthusiasm for platform expansion is ahead of near-term revenue realization.
The company’s reliance on expanding its sales organization as a primary growth driver introduces execution risk, as the productivity of recently hired territory managers—while encouraging with over 85% of 12+ month-tenured reps contributing to account base—is still early in its maturation curve, and management’s expectation of further step-up in productivity throughout 2026 and acceleration in 2027 assumes consistent hiring quality and retention, yet any slowdown in rep ramp-up due to market saturation, increased competition, or longer-than-expected sales cycles in system-level deals could undermine the projected acceleration in account adds, particularly as the regional health system initiative involves longer, more complex sales cycles that may not scale as quickly as bottom-up territory manager efforts, creating execution uncertainty in the company’s ability to sustain above-2025 growth rates in account acquisition.

CeriBell, Inc. faces significant near-term profitability headwinds driven by escalating and nonlinear IP litigation expenses, which totaled $5.6 million in Q1 2026—considerably higher than the $1–2 million quarterly run-rate seen in prior periods—and are expected to remain elevated through Q2 as the company prepares for and undergoes trial, with management acknowledging this as peak spend that will only moderate later in the year, creating a drag on adjusted EBITDA that could persist despite revenue growth and potentially delay cash-flow breakeven expectations if litigation costs remain elevated or increase due to unfavorable rulings or extended discovery.
The company’s growth trajectory remains heavily dependent on seasonal ICU census fluctuations, with management explicitly acknowledging sequential moderation in headband utilization during Q2 and Q3 due to warmer months reducing ICU admissions—a predictable but material headwind that offsets same-store growth gains and creates volatility in quarterly performance that may lead to periodic misses against consensus estimates, particularly as the guidance raise of $1 million was based on Q1 strength without fully accounting for the typical seasonal decline in utilization that has historically affected Q2 and Q3 results, making full-year achievement of the $112–116 million revenue range contingent on stronger-than-expected new account additions to offset predictable seasonal softness in usage per account.
Despite record net new account additions of 33 in Q1, CeriBell’s penetration in its core seizure market remains below 4% of the 6,000 U.S. hospitals offering acute care services, indicating that the addressable market expansion into new indications like delirium and LVO stroke may be overstated in near-term impact, as management conceded that commercial launch of delirium solution is not expected until Q4 2026 or Q1 2027 and that pediatric and neonate adoption requires months-long sales cycles similar to core accounts, meaning these initiatives are unlikely to contribute meaningfully to 2026 revenue beyond incremental usage within existing accounts, creating a risk that market enthusiasm for platform expansion is ahead of near-term revenue realization.
The company’s reliance on expanding its sales organization as a primary growth driver introduces execution risk, as the productivity of recently hired territory managers—while encouraging with over 85% of 12+ month-tenured reps contributing to account base—is still early in its maturation curve, and management’s expectation of further step-up in productivity throughout 2026 and acceleration in 2027 assumes consistent hiring quality and retention, yet any slowdown in rep ramp-up due to market saturation, increased competition, or longer-than-expected sales cycles in system-level deals could undermine the projected acceleration in account adds, particularly as the regional health system initiative involves longer, more complex sales cycles that may not scale as quickly as bottom-up territory manager efforts, creating execution uncertainty in the company’s ability to sustain above-2025 growth rates in account acquisition.

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password